Novel thiazolidinedione derivatives with anti-obesity effects: dual action as PTP1B inhibitors and PPAR-γ activators

Bioorg Med Chem Lett. 2010 Nov 15;20(22):6758-63. doi: 10.1016/j.bmcl.2010.08.130. Epub 2010 Sep 17.

Abstract

Benzylidene-2,4-thiazolidinedione derivatives with substitutions at both the ortho and para-positions of the phenyl group were synthesized as PTP1B inhibitors with IC(50) values in a low micromolar range. Compound 18l, the lowest, bore an IC(50) of 1.3 μM. In a peroxisome proliferator-activated receptor-γ (PPAR-γ) promoter reporter gene assay, 18l was found to activate the transcription of the reporter gene with potencies comparable to those of troglitazone, rosiglitazone, and pioglitazone. In vivo efficacy of 18l as an anti-obesity and hypoglycemic agent was evaluated in a mouse model system. Compound 18l significantly suppressed weight gain and significantly improved blood parameters such as TG, total cholesterol and NEFA without overt toxic effects.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Obesity Agents / pharmacology*
  • Blood Glucose / metabolism
  • Cholesterol / blood
  • Fatty Acids, Nonesterified / blood
  • Hypoglycemic Agents / pharmacology
  • Mice
  • PPAR gamma / agonists*
  • Protein Tyrosine Phosphatase, Non-Receptor Type 1 / antagonists & inhibitors*
  • Thiazolidinediones / pharmacology*
  • Triglycerides / blood

Substances

  • Anti-Obesity Agents
  • Blood Glucose
  • Fatty Acids, Nonesterified
  • Hypoglycemic Agents
  • PPAR gamma
  • Thiazolidinediones
  • Triglycerides
  • Cholesterol
  • Protein Tyrosine Phosphatase, Non-Receptor Type 1